These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 18473869)

  • 21. Interleukin-6 in rheumatoid arthritis.
    Nishimoto N
    Curr Opin Rheumatol; 2006 May; 18(3):277-81. PubMed ID: 16582692
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interleukin 6: from bench to bedside.
    Nishimoto N; Kishimoto T
    Nat Clin Pract Rheumatol; 2006 Nov; 2(11):619-26. PubMed ID: 17075601
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-interleukin-6 receptor antibody therapy in rheumatic diseases.
    Nakahara H; Nishimoto N
    Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):373-81. PubMed ID: 17214583
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interleukin-6: designing specific therapeutics for a complex cytokine.
    Garbers C; Heink S; Korn T; Rose-John S
    Nat Rev Drug Discov; 2018 Jun; 17(6):395-412. PubMed ID: 29725131
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of IL6 in rheumatoid arthritis and juvenile idiopathic arthritis.
    Mircic M; Kavanaugh A
    Exp Cell Res; 2011 May; 317(9):1286-92. PubMed ID: 21439276
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic uses of anti-interleukin-6 receptor antibody.
    Kang S; Tanaka T; Kishimoto T
    Int Immunol; 2015 Jan; 27(1):21-9. PubMed ID: 25142313
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting Interleukin-6 Signaling in Clinic.
    Kang S; Tanaka T; Narazaki M; Kishimoto T
    Immunity; 2019 Apr; 50(4):1007-1023. PubMed ID: 30995492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Cytokine Storm of Multicentric Castleman Disease.
    Fajgenbaum DC
    Adv Exp Med Biol; 2024; 1448():459-467. PubMed ID: 39117833
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease.
    Song SN; Tomosugi N; Kawabata H; Ishikawa T; Nishikawa T; Yoshizaki K
    Blood; 2010 Nov; 116(18):3627-34. PubMed ID: 20644113
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [New approaches to pharmacotherapy for rheumatoid arthritis: perspective for use of tocilizumab (monoclonal antibodies to interleukin-6 receptor)].
    Nasonov EL
    Ter Arkh; 2010; 82(5):64-71. PubMed ID: 20597275
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interleukin-6--a key mediator of systemic and local symptoms in rheumatoid arthritis.
    Cronstein BN
    Bull NYU Hosp Jt Dis; 2007; 65 Suppl 1():S11-5. PubMed ID: 17708739
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Anti-IL-6 receptor antibody].
    Nishimoto N
    Nihon Rinsho; 2005 May; 63 Suppl 5():723-7. PubMed ID: 15954436
    [No Abstract]   [Full Text] [Related]  

  • 33. Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody.
    Yoshizaki K; Nishimoto N; Mihara M; Kishimoto T
    Springer Semin Immunopathol; 1998; 20(1-2):247-59. PubMed ID: 9836380
    [No Abstract]   [Full Text] [Related]  

  • 34. Interrupting tocilizumab therapy-induced psoriasis-like eruption in a patient with rheumatoid arthritis and Crohn's disease.
    Saito Y; Hayashi S; Gonmori T; Hamasaki Y; Igawa K
    Int J Dermatol; 2020 May; 59(5):e159-e160. PubMed ID: 32034760
    [No Abstract]   [Full Text] [Related]  

  • 35. Spotlight on sirukumab for the treatment of rheumatoid arthritis: the evidence to date.
    Lazzerini PE; Capecchi PL; Guidelli GM; Selvi E; Acampa M; Laghi-Pasini F
    Drug Des Devel Ther; 2016; 10():3083-3098. PubMed ID: 27713619
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family.
    Mihara M; Kasutani K; Okazaki M; Nakamura A; Kawai S; Sugimoto M; Matsumoto Y; Ohsugi Y
    Int Immunopharmacol; 2005 Nov; 5(12):1731-40. PubMed ID: 16102523
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel therapy for Crohn's disease targeting IL-6 signalling.
    Ito H
    Expert Opin Ther Targets; 2004 Aug; 8(4):287-94. PubMed ID: 15268624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-interleukin-6 therapy in rheumatoid arthritis.
    Woodrick R; Ruderman EM
    Bull NYU Hosp Jt Dis; 2010; 68(3):211-7. PubMed ID: 20969554
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseases.
    Nirula A; Nilsen J; Klekotka P; Kricorian G; Erondu N; Towne JE; Russell CB; Martin DA; Budelsky AL
    Rheumatology (Oxford); 2016 Dec; 55(suppl 2):ii43-ii55. PubMed ID: 27856660
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical benefits of anti-human IL-6 receptor antibody therapy].
    Nishimoto N
    Clin Calcium; 2007 Apr; 17(4):562-8. PubMed ID: 17404486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.